The complaint

The case is Opus Genetics, Inc. v. Sandoz Inc., No. 3:26-cv-12469 (D.N.J.). The complaint is Document 1, filed September 21, 2026, and it is 15 pages. A docket entry on September 22, 2026 states that Judge Zahid N. Quraishi and Magistrate Judge Rukhsanah L. Singh were added.

The complaint names two plaintiffs. It says FamyGen Life Sciences, Inc. is a Nevada corporation, the registered holder of approved NDA No. 217064 for RYZUMVI, and the exclusive licensee of the patents-in-suit with a right to enforce. It says Opus Genetics, Inc. is a Delaware corporation with a place of business in Durham, North Carolina, and is the assignee of the patents-in-suit. The complaint alleges, upon information and belief, that Sandoz Inc. is a Delaware corporation with a principal place of business in Princeton, New Jersey, and that Sandoz is in the business of, among other things, importing, manufacturing, and selling generic versions of branded pharmaceutical products in and for the U.S. market.

The complaint pleads subject matter jurisdiction under 28 U.S.C. 1331, 1338(a), 2201, and 2202. It alleges, upon information and belief, that Sandoz has a principal place of business in New Jersey, is registered to do business in New Jersey, and has a regular and established place of business in Princeton, New Jersey. It says Sandoz did not contest personal jurisdiction or venue in No. 3:25-cv-1895 or No. 3:26-cv-04811. It pleads venue under 28 U.S.C. 1391 and/or 1400(b).

The drug and the ANDA

The complaint says FamyGen holds NDA No. 217064 for RYZUMVI (phentolamine ophthalmic solution, 0.75%), which the FDA approved on September 25, 2023. It describes RYZUMVI 0.75% as a sterile solution for topical ophthalmic use containing 1% phentolamine mesylate, equivalent to 0.75% phentolamine. It says RYZUMVI is indicated for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists, such as phenylephrine, or parasympatholytic agents, such as tropicamide.

The complaint says this is an action for patent infringement under 35 U.S.C. 271 and 281, and for a declaratory judgment under 28 U.S.C. 2201 and 2202, arising from Sandoz's submission of ANDA No. 219888 to the FDA. It says the ANDA seeks approval to manufacture, use, import, distribute, offer to sell, and/or sell generic versions of RYZUMVI before the '810 and '126 patents expire. It alleges, upon information and belief, that Sandoz filed or caused to be filed ANDA No. 219888 under 21 U.S.C. 355(j), seeking approval to engage in the commercial manufacture, use, and sale of a product intended to be a generic version of RYZUMVI. It alleges, upon information and belief, including based on requirements of the FDA, that the ANDA seeks approval of a product, and of a label and indications, that are the same, or substantially the same, as RYZUMVI.

What the patents cover

The complaint says the plaintiffs intend to list both patents in the Orange Book for NDA No. 217064. It says the USPTO issued U.S. Patent 12,721,810 on September 1, 2026, and U.S. Patent 12,734,126 on September 15, 2026. Both are titled "Aqueous Ophthalmic Solutions of Phentolamine and Medical Uses Thereof." The complaint says the claims of each patent are valid and enforceable, that Opus is the assignee of each through an assignment recorded at Reel 73069, Frame 0550, and that FamyGen is the exclusive licensee of each. Each face states that the patent is subject to a terminal disclaimer and that the term is extended or adjusted under 35 U.S.C. 154(b) by 0 days. Each patent states that it has 30 claims. The '810 patent is application No. 19/190,234, and the '126 patent is application No. 19/190,199. Both applications were filed on April 25, 2025.

Claim 1 of U.S. Patent 12,721,810 is a method of making an aqueous ophthalmic solution by combining phentolamine or a pharmaceutically acceptable salt thereof, at a concentration of from about 0.1% (w/v) to about 4% (w/v), at least one polyol compound selected from mannitol, glycerol, propylene glycol, ethylene glycol, sorbitol, and xylitol, at least one buffer at a concentration of from about 0.1 mM to about 10 mM, and water. The claim requires that the solution not contain any additional ingredient that is a chelating agent and not contain any additional ingredient that is a stabilizer. Claim 2 adds adjusting the pH to about 4.0 to about 7.5. Claim 3, which depends on claim 2, narrows the solution to one that comprises about 1% (w/v) phentolamine mesylate, a buffer that comprises sodium acetate, and about 4% (w/v) mannitol. Claims 7 and 19 are methods of making that use "consisting essentially of," and claim 13 uses "consisting of." Claims 25 through 30 each claim an aqueous ophthalmic solution made by the method of one of claims 13, 14, 15, 19, 20, and 21.

Claim 1 of U.S. Patent 12,734,126 is a method of pupil reduction comprising administering to a subject an effective amount of an aqueous ophthalmic solution. The method comprises storing the solution at a temperature in the range of 2-8 degrees C and administrating the solution to the eye of a patient in the form of an eye drop. The solution comprises about 0.1% (w/v) to about 4% (w/v) of phentolamine or a pharmaceutically acceptable salt thereof, at least one polyol compound selected from mannitol, glycerol, propylene glycol, ethylene glycol, sorbitol, and xylitol, about 0.1 mM to about 10 mM of at least one buffer, and water. The claim requires that the solution not contain any additional ingredient that is a chelating agent and not contain any additional ingredient that is a stabilizer, and that the solution have a pH of about 4.0 to about 7.5. Claim 25, which depends on claim 1, narrows the method to a solution in which about 1% (w/v) phentolamine mesylate is present, the buffer comprises sodium acetate, and about 4% (w/v) mannitol is present. Claims 28, 29, and 30 add limits stated in the alternative: less than 2% of the phentolamine mesylate degrades upon storage at 25 degrees C for 12 weeks, less than 2% degrades upon storage at 25 degrees C for 24 weeks, or less than 7% degrades upon storage at 40 degrees C for 12 weeks.

The counts

Count I is headed "Infringement of the '810 Patent Under 35 U.S.C. 271(e)(2)." The complaint alleges, upon information and belief, that Sandoz filed ANDA No. 219888 seeking approval to manufacture, use, import, offer to sell and/or sell the ANDA product before the '810 patent expires, and that Sandoz has or will file a certification under 21 U.S.C. 355(j)(2)(A)(vii)(IV) and 21 C.F.R. 314.94(a)(12)(i)(A)(4) alleging that the claims of the '810 patent are invalid, unenforceable and/or will not be infringed. It alleges, upon information and belief, that Sandoz has represented to the FDA that the ANDA product is pharmaceutically and therapeutically equivalent to RYZUMVI, and that Sandoz became aware of the '810 patent no later than the day the patent issued. It alleges, upon information and belief, that under 35 U.S.C. 271(e)(2)(A) Sandoz has infringed at least one claim of the '810 patent by submitting the ANDA. It alleges, upon information and belief, that if the ANDA is approved, Sandoz intends to and will manufacture, use, import, offer to sell and/or sell the ANDA product in the United States, and will directly or indirectly infringe one or more claims of the '810 patent under 35 U.S.C. 271(a), (b), (c), and/or (g), unless the court orders that the effective date of any FDA approval be no earlier than the expiration of the '810 patent and any additional periods of exclusivity. The complaint says the plaintiffs will be irreparably harmed, that they have no adequate remedy at law, and that the case is an exceptional one, and that they are entitled to reasonable attorneys' fees under 35 U.S.C. 285.

Count II is headed "Declaratory Judgment of Infringement of the '810 Patent." It arises under 28 U.S.C. 2201 and 2202. The complaint says Sandoz has made, and will continue to make, substantial preparation in the United States to manufacture, use, offer to sell, sell, and/or import the ANDA product before the '810 patent expires, including by submitting the ANDA. It alleges, upon information and belief, that any commercial manufacture, use, offer for sale, sale, and/or importation will directly infringe, contributorily infringe, and/or induce infringement of at least one claim of the '810 patent under 35 U.S.C. 271(a), (b), (c), and/or (g). It seeks a declaration that future commercial manufacture, use, offer of sale, sale, and/or importation will constitute infringement of at least one claim under those subsections.

Count III is headed "Infringement of the '126 Patent Under 35 U.S.C. 271(e)(2)." The complaint alleges, upon information and belief, the same categories of conduct as in Count I, directed to the '126 patent: filing the ANDA for approval before that patent expires, a certification that its claims are invalid, unenforceable and/or will not be infringed, a representation of pharmaceutical and therapeutic equivalence to RYZUMVI, knowledge of the patent no later than issuance, and infringement of at least one claim under 35 U.S.C. 271(e)(2)(A) by the submission. It alleges, upon information and belief, that if the ANDA is approved, Sandoz will directly or indirectly infringe one or more claims of the '126 patent under 35 U.S.C. 271(a), (b), and/or (c), unless the court orders that any approval be effective no earlier than the expiration of the '126 patent and any additional periods of exclusivity. The complaint says the plaintiffs will be irreparably harmed, that they have no adequate remedy at law, and that the case is exceptional under 35 U.S.C. 285.

Count IV is headed "Declaratory Judgment of Infringement of the '126 Patent." It arises under 28 U.S.C. 2201 and 2202. The complaint says Sandoz has made, and will continue to make, substantial preparation to manufacture, use, offer to sell, sell, and/or import the ANDA product before the '126 patent expires, including by submitting the ANDA. It alleges, upon information and belief, that commercial manufacture, use, offer for sale, sale, and/or importation will directly infringe, contributorily infringe, and/or induce infringement of at least one claim of the '126 patent under 35 U.S.C. 271(a), (b), and/or (c). It seeks a declaration that future commercial manufacture, use, offer of sale, sale, and/or importation will constitute infringement of at least one claim under those subsections.

Relief sought

The prayer asks the court to enter judgment that, under 35 U.S.C. 271(e)(2), Sandoz has infringed at least one claim of each patent by submitting ANDA No. 219888. It asks for an order, under 35 U.S.C. 271(e)(4)(A), that the effective date of any FDA approval be no earlier than the expiration of the patents and any additional periods of exclusivity, or any later date the court determines. It asks the court to enjoin Sandoz, and all persons acting in concert with Sandoz, from manufacturing, using, offering for sale, or selling the ANDA product in the United States, or importing it, until the expiration of the patents, including any additional periods of exclusivity, or any later date the court determines, under 35 U.S.C. 271(e)(4)(B). It asks for a declaration that commercial manufacture, use, offer for sale, or sale in the United States, or importation, or inducing or contributing to that conduct, would infringe one or more claims under one or more of 35 U.S.C. 271(a), (b), (c), and (g). It asks for a declaration that the patents remain valid and enforceable, a declaration that the case is exceptional, with attorneys' fees under 35 U.S.C. 271(e)(4) and 285, an award of costs, expenses, and disbursements, further appropriate relief under 35 U.S.C. 271(e)(4), and any further relief the court deems just and proper.

The earlier actions

The complaint says the plaintiffs previously filed two actions in the District of New Jersey over the same ANDA No. 219888. It calls No. 3:25-cv-1895, filed March 14, 2025, the First Suit. It says that action asserted U.S. Patents 9,795,560, 10,278,918, 10,772,829, 11,090,261, 11,844,858, 11,400,077, 12,201,615, and 12,201,616, and that it was filed in response to letters from Sandoz dated January 31, 2025, and February 27, 2025. The complaint describes those letters as purporting to include a notice of Paragraph IV certification regarding certain of those patents, under Section 505(j)(2)(B) and 21 C.F.R. 314.95. It calls No. 3:26-cv-04811, filed April 29, 2026, the Second Suit, and says that action included counts of infringement of U.S. Patents 12,576,066 and 12,576,067. A certification under Local Civil Rule 11.2 states that those two actions are pending in the District of New Jersey, concern the same ANDA, and allege patent infringement against the same defendant.

The docket

The docket shows an October 9, 2026 entry labeled "Answer to Complaint AND Counterclaim." It shows an October 20, 2026 entry labeled "Stipulation." On October 21, 2026, it shows an entry labeled "Order AND ~Util - Create Case Association" and a minute entry labeled "Terminate Civil Case."

What to watch next

Watch for any further entry in No. 3:26-cv-12469 after the October 21, 2026 docket entries. The case can end at any time, including by settlement or voluntary dismissal.